bigespas@bigespas.com
+44 20 38077948
+44 20 38077948
LEAVE YOUR INQUIRY
Leave your contact details and we will contact you.
Consent to privacy policy
Сure for Alzheimer's is coming..
Сure for Alzheimer's is coming..
About
Leave your inquiry
BIGESPAS Ltd, is a UK based private company established in 2020 to run an anti-Alzheimer drug development project. The company holds US 12 084 440 B2 patent which secures a know-how related to the discovered polymorph DMB-I of Latrepirdine.
In 2023 BIGESPAS Ltd has started Phase II trial on its drug product Dimebon® DMB-I based on successful data received on previous animal studies stage.
In 2025 The Company completed the 28 weeks Phase II clinical trial evaluating the safety and efficacy of DMB-I in 135 patients with mild-to-moderate Alzheimer’s disease. The outcome is a substantial cognitive improvement over placebo (i.e., Memantine), with measurable patient response observed from Week 12 and sustained throughout the treatment period.
In 2023 BIGESPAS Ltd has started Phase II trial on its drug product Dimebon® DMB-I based on successful data received on previous animal studies stage.
In 2025 The Company completed the 28 weeks Phase II clinical trial evaluating the safety and efficacy of DMB-I in 135 patients with mild-to-moderate Alzheimer’s disease. The outcome is a substantial cognitive improvement over placebo (i.e., Memantine), with measurable patient response observed from Week 12 and sustained throughout the treatment period.